DeepMed Research

SXC-2023

Generic Name: SXC-2023

Clinical Trials

SXC-2023 Cocaine Interaction Study

Phase 1

Completed

Conditions: Cocaine Use Disorder

Interventions: Drug: SXC-2023 Placebo
Drug: SXC-2023

First Posted Date: 2024-04-02

Last Posted Date: 2025-05-20

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 17

Registration Number: NCT06343532

Locations: 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

Phase 2

Completed

Conditions: Impulse Control Disorders

Interventions: Drug: SXC-2023
Drug: Placebos

First Posted Date: 2019-03-25

Last Posted Date: 2020-07-17

Lead Sponsor: Promentis Pharmaceuticals, Inc.

Target Recruit Count: 34

Registration Number: NCT03887429

Locations: 🇺🇸
Celerion Inc., Lincoln, Nebraska, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

A Study in Patients With Trichotillomania

Phase 2

Completed

Conditions: Trichotillomania

Interventions: Drug: SXC-2023
Drug: Placebo

First Posted Date: 2019-01-09

Last Posted Date: 2021-10-28

Lead Sponsor: Promentis Pharmaceuticals, Inc.

Target Recruit Count: 128

Registration Number: NCT03797521

Locations: 🇺🇸
Finger Lakes Clinical Research, Rochester, New York, United States
🇺🇸
Integrative Clinical Trials, LLC, Brooklyn, New York, United States
🇺🇸
Artemis Institute for Clinical Research, Riverside, California, United States

and more 10 locations

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: SXC-2023
Drug: Placebo

First Posted Date: 2018-05-31

Last Posted Date: 2018-10-16

Lead Sponsor: Promentis Pharmaceuticals, Inc.

Target Recruit Count: 40

Registration Number: NCT03542435

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: SXC-2023
Drug: Placebo oral capsule

First Posted Date: 2017-10-04

Last Posted Date: 2019-09-26

Lead Sponsor: Promentis Pharmaceuticals, Inc.

Target Recruit Count: 48

Registration Number: NCT03301298

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy